Fycompa Brand Extension: Eisai Launched FYCOMPA® (perampanel) Oral Suspension

Fycompa Brand Extension: Eisai Launched FYCOMPA® (perampanel) Oral Suspension

Positioning of New Formulation:
Option for Patients with Epilepsy Who May Have Difficulty Swallowing Tablets or Prefer Liquids.

Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty swallowing tablets or prefer liquids. FYCOMPA CIII is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. This new option, which comes in a single bottle with an adapter and syringes to measure the right dose, was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2016.

FYCOMPA is an oral medication and the first and only FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The precise mechanism by which FYCOMPA exerts its antiepileptic effects in humans has not been fully elucidated.

FYCOMPA, approved in 47 countries, was discovered and developed by Eisai. Over 60,000 patients globally have been treated with FYCOMPA.

Fycompa Additional Indication Approval >> View

Few related case studies on Additional Indication Approval >> View